AU2013322612B2 - Modulators of androgen synthesis - Google Patents

Modulators of androgen synthesis Download PDF

Info

Publication number
AU2013322612B2
AU2013322612B2 AU2013322612A AU2013322612A AU2013322612B2 AU 2013322612 B2 AU2013322612 B2 AU 2013322612B2 AU 2013322612 A AU2013322612 A AU 2013322612A AU 2013322612 A AU2013322612 A AU 2013322612A AU 2013322612 B2 AU2013322612 B2 AU 2013322612B2
Authority
AU
Australia
Prior art keywords
day
acid
pharmaceutical composition
therapeutic compound
disorder associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013322612A
Other languages
English (en)
Other versions
AU2013322612A2 (en
AU2013322612A1 (en
Inventor
Suzanne Jane Dilly
Gregory Alan Stoloff
Paul Christopher Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tangent Reprofiling Ltd
Original Assignee
Tangent Reprofiling Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tangent Reprofiling Ltd filed Critical Tangent Reprofiling Ltd
Publication of AU2013322612A2 publication Critical patent/AU2013322612A2/en
Publication of AU2013322612A1 publication Critical patent/AU2013322612A1/en
Application granted granted Critical
Publication of AU2013322612B2 publication Critical patent/AU2013322612B2/en
Priority to AU2017221819A priority Critical patent/AU2017221819B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2013322612A 2012-09-26 2013-09-26 Modulators of androgen synthesis Active AU2013322612B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017221819A AU2017221819B2 (en) 2012-09-26 2017-08-31 Modulators of androgen synthesis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261705790P 2012-09-26 2012-09-26
US61/705,790 2012-09-26
US201361871662P 2013-08-29 2013-08-29
US61/871,662 2013-08-29
PCT/EP2013/070106 WO2014049071A1 (en) 2012-09-26 2013-09-26 Modulators of androgen synthesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017221819A Division AU2017221819B2 (en) 2012-09-26 2017-08-31 Modulators of androgen synthesis

Publications (3)

Publication Number Publication Date
AU2013322612A2 AU2013322612A2 (en) 2015-04-09
AU2013322612A1 AU2013322612A1 (en) 2015-04-09
AU2013322612B2 true AU2013322612B2 (en) 2017-06-01

Family

ID=49293617

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013322612A Active AU2013322612B2 (en) 2012-09-26 2013-09-26 Modulators of androgen synthesis
AU2017221819A Active AU2017221819B2 (en) 2012-09-26 2017-08-31 Modulators of androgen synthesis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017221819A Active AU2017221819B2 (en) 2012-09-26 2017-08-31 Modulators of androgen synthesis

Country Status (14)

Country Link
US (4) US9072743B2 (enExample)
EP (1) EP2900270B1 (enExample)
JP (2) JP6434410B2 (enExample)
CN (1) CN104797271B (enExample)
AU (2) AU2013322612B2 (enExample)
BR (1) BR112015006727B1 (enExample)
CA (1) CA2886132C (enExample)
ES (1) ES2734554T3 (enExample)
HK (1) HK1211868A1 (enExample)
IL (2) IL237892B (enExample)
MX (1) MX367782B (enExample)
NZ (1) NZ706067A (enExample)
PL (1) PL2900270T3 (enExample)
WO (1) WO2014049071A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1211868A1 (en) 2012-09-26 2016-06-03 Tangent Reprofiling Limited Modulators of androgen synthesis
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
CA2950800C (en) * 2014-05-09 2023-01-10 Tangent Reprofiling Limited Modulators of androgen synthesis
SG11201906735RA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
JP2020516283A (ja) * 2017-04-11 2020-06-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒドロキシステロイド（１７−ベータ）デヒドロゲナーゼ（ｈｓｄ１７ｂ）ファミリーのメンバーのモジュレーターの活性をスクリーニングするためのアッセイ
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
CN112020556A (zh) 2018-03-21 2020-12-01 瑞泽恩制药公司 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066196A1 (en) * 2003-12-30 2005-07-21 Ranbaxy Laboratories Limited Amorphous form of finasteride and processes for its preparation
CN101366705A (zh) * 2008-09-28 2009-02-18 浙江大学 利培酮透皮吸收贴片
US20090143344A1 (en) * 2007-12-04 2009-06-04 Yeong-Ming Chang Methods for treating or preventing symptoms of hormonal variations
US8153648B2 (en) * 2008-01-03 2012-04-10 Gador S.A. Solid and crystalline dutasteride and processes for preparation thereof
WO2012109387A1 (en) * 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
WO1991002527A1 (en) * 1989-08-21 1991-03-07 Beth Israel Hospital Association Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6319950B1 (en) 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
JPH1192343A (ja) * 1997-09-22 1999-04-06 Shiseido Co Ltd 毛髪成長期延長剤
JPH11209279A (ja) * 1998-01-05 1999-08-03 Natural Ltd As 体重減少および肥満処置の方法
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US6977271B1 (en) * 2001-08-30 2005-12-20 Health Research, Inc. Method for inhibition of angiogenesis and vasculogenesis
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
MXPA04007752A (es) * 2002-02-08 2005-06-17 Abbott Lab Terapia de combinacion para tratamiento de esquizofrenia.
EP1626703A2 (en) * 2003-05-22 2006-02-22 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
CN100548271C (zh) 2004-01-20 2009-10-14 阿勒根公司 用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
BRPI0611322A2 (pt) * 2005-05-31 2010-08-31 Orexigen Therapeutics Inc métodos e composicões para controlar distúrbios psicóticos
WO2008034129A2 (en) * 2006-09-15 2008-03-20 Cornell Research Foundation Inc. Treatment of cancer or obesity with conjugated linoleic acids
WO2009134383A2 (en) * 2008-05-01 2009-11-05 Complexa Inc. Vinyl substituted fatty acids
ES2443045T5 (es) 2009-04-20 2021-05-10 Allergan Inc Hidrogeles de fibroína de seda y usos de éstos
WO2012026663A1 (ko) * 2010-08-25 2012-03-01 이화여자대학교 산학협력단 운데실렌산, 공액리놀레산 및/또는 공액리놀레산 이성질체를 포함하는 항암보조제
WO2014027973A1 (en) * 2012-08-14 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Paliperidone oral solution
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
HK1211868A1 (en) 2012-09-26 2016-06-03 Tangent Reprofiling Limited Modulators of androgen synthesis
CA2950800C (en) 2014-05-09 2023-01-10 Tangent Reprofiling Limited Modulators of androgen synthesis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066196A1 (en) * 2003-12-30 2005-07-21 Ranbaxy Laboratories Limited Amorphous form of finasteride and processes for its preparation
US20090143344A1 (en) * 2007-12-04 2009-06-04 Yeong-Ming Chang Methods for treating or preventing symptoms of hormonal variations
US8153648B2 (en) * 2008-01-03 2012-04-10 Gador S.A. Solid and crystalline dutasteride and processes for preparation thereof
CN101366705A (zh) * 2008-09-28 2009-02-18 浙江大学 利培酮透皮吸收贴片
WO2012109387A1 (en) * 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia

Also Published As

Publication number Publication date
JP2015532920A (ja) 2015-11-16
US20150258095A1 (en) 2015-09-17
PL2900270T3 (pl) 2019-09-30
AU2013322612A2 (en) 2015-04-09
US9585887B2 (en) 2017-03-07
JP6434410B2 (ja) 2018-12-05
BR112015006727B1 (pt) 2022-08-16
IL237892A0 (en) 2015-05-31
JP2019052159A (ja) 2019-04-04
HK1211868A1 (en) 2016-06-03
CN104797271A (zh) 2015-07-22
US9072743B2 (en) 2015-07-07
CA2886132A1 (en) 2014-04-03
BR112015006727A8 (pt) 2019-08-27
EP2900270A1 (en) 2015-08-05
MX367782B (es) 2019-09-04
IL266446A (en) 2019-06-30
US20180064713A1 (en) 2018-03-08
US9808462B2 (en) 2017-11-07
CN104797271B (zh) 2020-03-06
MX2015003899A (es) 2015-11-25
CA2886132C (en) 2023-03-21
US20140088120A1 (en) 2014-03-27
ES2734554T3 (es) 2019-12-10
IL237892B (en) 2019-05-30
AU2013322612A1 (en) 2015-04-09
BR112015006727A2 (pt) 2017-07-04
US20170189407A1 (en) 2017-07-06
NZ706067A (en) 2016-07-29
WO2014049071A1 (en) 2014-04-03
JP6734346B2 (ja) 2020-08-05
AU2017221819A1 (en) 2017-09-21
AU2017221819B2 (en) 2019-05-02
EP2900270B1 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
AU2017221819B2 (en) Modulators of androgen synthesis
US10111877B2 (en) Modulators of androgen synthesis
CA2950800C (en) Modulators of androgen synthesis
PT2164844E (pt) Derivados de pirimidinil-piridazinona
JP2017514816A5 (enExample)
CA2607260A1 (en) Compositions and methods for treatment for neoplasms
US20100305156A1 (en) Inhibitors of c-met protein kinase
CN102448968A (zh) C-met蛋白激酶的取代的吡唑抑制剂

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 17 MAR 2015

FGA Letters patent sealed or granted (standard patent)